2-ethylamino-2-methyl-propionamide | 1170701-06-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-ethylamino-2-methyl-propionamide
• 英文别名: 2-(Ethylamino)-2-methylpropanamide
• CAS: 1170701-06-0
• 化学式: C₆H₁₄N₂O
• 分子量: 130.19
• InChiKey: FTKUJZVWJCGMRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2,4-二氯苯基)-5-对氯苯基-4-甲基-吡唑-3-甲酸 、 2-ethylamino-2-methyl-propionamide 生成 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]-1-ethyl-5,5-dimethyl-1,5-dihydroimidazol-4-one
  参考文献：
  名称：

  Imidazol-4-one and Imidazole-4-thione Compounds

  摘要：

  本发明涉及公式（I）的咪唑-4-酮或咪唑-4-硫酮化合物，其中X、R1、R2、R3、R4、R5和R6如本文所定义。本发明还揭示了使用这些化合物治疗大麻素受体介导的疾病的方法。

  公开号：

  US20100113546A1

文献信息

• Imidazol-4-one and imidazole-4-thione compounds
  申请人：Shia Kak-Shan

  公开号：US08354442B2

  公开（公告）日：2013-01-15

  Imidazol-4-one or imidazole-4-thione compounds of formula (I): wherein X, R1, R2, R3, R4, R5, and R6 are defined herein. Also disclosed is a method for treating a cannabinoid receptor-mediated disorder with these compounds.

  式(I)中的咪唑-4-酮或咪唑-4-硫酮化合物：其中X，R1，R2，R3，R4，R5和R6在此定义。还公开了使用这些化合物治疗大麻素受体介导的疾病的方法。
• Discovery of 2-[5-(4-Chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1<i>H</i>-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an Active Metabolite. A Novel, Potent and Selective Cannabinoid-1 Receptor Inverse Agonist with High Antiobesity Efficacy in DIO Mice
  作者：Chien-Huang Wu、Ming-Shiu Hung、Jen-Shin Song、Teng-Kuang Yeh、Ming-Chen Chou、Cheng-Ming Chu、Jiing-Jyh Jan、Min-Tsang Hsieh、Shi-Liang Tseng、Chun-Ping Chang、Wan-Ping Hsieh、Yinchiu Lin、Yen-Nan Yeh、Wan-Ling Chung、Chun-Wei Kuo、Chin-Yu Lin、Horng-Shing Shy、Yu-Sheng Chao、Kak-Shan Shia

  DOI：10.1021/jm900471u

  日期：2009.7.23

  By using the active metabolite 5 as an initial template, further structural modifications led to the identification of the titled compound 24 (BPR-890) as a highly potent CB I inverse agonist possessing an excellent CB2/1 selectivity and remarkable in vivo efficacy in diet-induced obese mice with a minimum effective dose as low as 0.03 mg/kg (po qd) at the end of the 30-day chronic study. Current SAR studies along with those of many existing rimonabant-mimicking molecules imply that around the pyrazole C3-position, a rigid and deep binding pocket should exist for CB1 receptor. In addition, relative to the conventional carboxamide carbonyl, serving as a key hydrogen-bond acceptor during ligand-CB1 receptor interaction, the corresponding polarizable thione carbonyl might play a more critical role in stabilizing the Asp366-Lys192 salt bridge in the proposed CB1-receptor homology model and inducing significant selectivity for CB1R over CB2R.
• AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
  申请人：Exelixis, Inc.

  公开号：EP1934174A1

  公开（公告）日：2008-06-25
• 6-MORPHOLINYL-2-PYRAZOLYL-9H-PURINE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3277682B1

  公开（公告）日：2019-04-24
• MEK Inhibitors and Methods of Their Use
  申请人：Exelixis, Inc.

  公开号：US20190144382A1

  公开（公告）日：2019-05-16

  Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.